Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythromycin ototoxicity

P Thompson, R P Wood, L Bergstrom

    The Journal of Otolaryngology
    |February 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Erythromycin is a safe antibiotic, but can cause hearing loss (ototoxicity), especially with high oral doses in patients with kidney problems. This hearing loss is usually reversible.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival.

    Cancer prevention research (Philadelphia, Pa.)·2011
    Same author

    CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
    Same author

    Appraisal of Meconium at Delivery: A look at intervention strategies.

    Canadian family physician Medecin de famille canadien·2011
    Same author

    Focal structural changes and cognitive dysfunction in juvenile myoclonic epilepsy.

    Neurology·2011
    Same author

    The nature of trauma memories in acute stress disorder in children and adolescents.

    Journal of child psychology and psychiatry, and allied disciplines·2010
    Same author

    An evaluation of changes over time in serum creatine kinase activity and C-reactive protein concentration in dogs undergoing hemilaminectomy or ovariohysterectomy.

    Journal of the South African Veterinary Association·2010
    Same journal

    Primary large cell neuroendocrine carcinoma of the submandibular gland: unique presentation and surprising treatment response.

    The Journal of otolaryngology·2008
    Same journal

    Hearing recovery after meningitis.

    The Journal of otolaryngology·2008
    Same journal

    Endoscopic transnasal sphenopalatine arterial ligation for intractable posterior epistaxis in a young child.

    The Journal of otolaryngology·2008
    Same journal

    [Non-functional parathyroid cyst].

    The Journal of otolaryngology·2008
    Same journal

    Cacosmia secondary to an olfactory groove meningioma.

    The Journal of otolaryngology·2008
    Same journal

    Hemangioma of the vocal cords: review of two cases.

    The Journal of otolaryngology·2008
    See all related articles

    Area of Science:

    • Otolaryngology
    • Pharmacology
    • Nephrology

    Background:

    • Erythromycin is a widely used antibiotic with a generally favorable safety profile.
    • While rare, ototoxicity is a potential complication of erythromycin administration.
    • Previous reports of erythromycin-induced ototoxicity primarily involved intravenous administration.

    Observation:

    • A case study of an 18-year-old female patient with severe renal failure is presented.
    • The patient received high doses of an oral erythromycin preparation.
    • The patient developed sensorineural hearing loss.

    Findings:

    • The patient's hearing loss was determined to be sensorineural.
    • The ototoxic effects were associated with high-dose oral erythromycin in the context of renal failure.

    Related Experiment Videos

  • The hearing loss was reversible upon discontinuation of the medication.

    • Implications:

    • This case highlights the potential for ototoxicity from oral erythromycin, particularly in patients with impaired renal function.
    • Clinicians should be aware of this rare but serious side effect and monitor hearing in at-risk patients.
    • Further research may be warranted to elucidate the mechanisms and risk factors for erythromycin-induced ototoxicity.